Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term fluticasone propionate

Aims: The primary aim of the objective of the study was to determine the effects of long-term treatment with the recommended dose of inhaled fluticasone propionate spray usage on bone mineral status in children with asthma. Methods: This cross-sectional, case–control study was of 270 pre-pubertal children with asthma, who had used inhaled fluticasone propionate at a mean daily dose of 200μg (range: 200–350μg) for at least 5 years. The bone mineral density (BMD) of the lumbar spine was measured by dual-energy X-ray absorptiometry (DEXA). The results were compared to untreated controls (n=200), who were newly diagnosed children with asthma without any corticosteroid treatment. Results: The 270 study patients (175 males) were aged between 6 and 13 years. The average age (±SEM) was 9.2±0.6 years, and the mean (±SEM) steroid dosage used was 183.3±57.0μg daily, with 236.5±17.2g total steroid use during treatment. Between the study and the control groups, no significant difference was observed in BMD (p>0.05). Conclusion: The findings suggest that long-term periodical treatment for 5 years with inhaled fluticasone propionate, 100μg twice daily, in children with asthma revealed no negative effect on bone mineral density by using DEXA(AU)

Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term fluticasone propionate.

AIMS: The primary aim of the objective of the study was to determine the effects of long-term treatment with the recommended dose of inhaled fluticasone propionate spray usage on bone mineral status in children with asthma. METHODS: This cross-sectional, case-control study was of 270 pre-pubertal children with asthma, who had used inhaled fluticasone propionate at a mean daily dose of 200 µg (range: 200-350 µg) for at least 5 years. The bone mineral density (BMD) of the lumbar spine was measured by dual-energy X-ray absorptiometry (DEXA). The results were compared to untreated controls (n=200), who were newly diagnosed children with asthma without any corticosteroid treatment. RESULTS: The 270 study patients (175 males) were aged between 6 and 13 years. The average age (±SEM) was 9.2±0.6 years, and the mean (±SEM) steroid dosage used was 183.3±57.0 µg daily, with 236.5±17.2 g total steroid use during treatment. Between the study and the control groups, no significant difference was observed in BMD (p>0.05). CONCLUSION: The findings suggest that long-term periodical treatment for 5 years with inhaled fluticasone propionate, 100 µg twice daily, in children with asthma revealed no negative effect on bone mineral density by using DEXA.

Bone age in children with nocturnal enuresis.

It is widely believed that nocturnal enuresis is caused by a hereditary delay in maturation of the various organ systems. In this study, growth and bone age were investigated in enuretic children. There was a significant bone age lag in the enuretic group compared to the control subjects of similar age (8.15 +/- 1.56 years vs 9.45 +/- 2.17 years, p < 0.05). It has been suggested that skeletal maturation also are retarded in nocturnal enuresis; and, it may be caused by the delayed maturation in regulatory functions of the central nervous system

Analysis of heart rate variability in children with primary nocturnal enuresis.

Although nocturnal enuresis is probably the most common developmental disorder in children, the pathogenesis and management remain unclear. Autonomic dysfunction is one of the proposed mechanisms for nocturnal enuresis in children. The objective of current study was to evaluate autonomic nervous system functions in enuretic children. Twenty-four-hour ambulatory electrocardiographic recordings were obtained, and the time domain variables of HRV were calculated. The results of the present study suggest that sympathetic nervous system hyperactivity is present in enuretic children. This may explain why some enuretic children do not respond to anticholinergic medications. If these conflicting results are confirmed by large-scale clinical studies, Holter ECG examinations may be used for rational approaches in treatment of nocturnal enuresis.

The effect of iron supplementation on visual-evoked potentials in infants with iron-deficiency anemia.

Flash visual-evoked potentials were studied in 20 infants with iron-deficiency anemia to determine the effect of iron deficiency on visual function by using visual-evoked potentials in this type of anemia. After iron therapy for 12 weeks, visual-evoked potentials were retested in these otherwise healthy infants. All infants showed an excellent hematological response to iron therapy. Post-treatment visual-evoked potential N2 latencies (negative deflections) decreased significantly compared to the pre-treatment values (p < 0.05). These results suggest that iron-deficiency anemia causes subclinical visual impairment, and visual-evoked potentials may be a useful non-invasive means of detecting subtle effects of nutritional deficiencies and monitoring the nutritional status of infants.

Brainstem auditory-evoked potentials in iron-deficiency anemia.

Slight-to-moderate impairments may be observed in mental and motor developments of infants with iron- deficiency anemia. Brainstem auditory-evoked potentials provide a noninvasive means of examining the auditory aspect of the central nervous system functions. In this study the effect of iron-deficiency anemia on auditory functions was investigated by using brainstem auditory-evoked potentials. Brainstem auditory-evoked potentials of the 20 iron-deficient infants were not significantly different from those of the control group that included 20 healthy age-matched infants. Furthermore, there was not a statistically significant difference between the brainstem auditory-evoked potentials of the study group performed before and 3 months after oral iron therapy. Although we could not demonstrate a hearing loss in infants with moderate iron-deficiency anemia in this study, the relationship between severe iron-deficiency anemia and hearing loss or auditory dysfunction remains to be determined.

Fiberoptic phototherapy versus conventional daylight phototherapy for hyperbilirubinemia of term newborns.

The efficacy and wavelengths of fiberoptic phototherapy and conventional daylight phototherapy were compared in a relatively larger series of term newborns with nonhemolytic and significant hyperbilirubinemia than reported in previous studies. One hundred and nine term newborns were randomly assigned to receive either fiberoptic phototherapy on a fiberoptic phototherapy pad or overhead conventional phototherapy consisting of five daylight fluorescent lamps. Although the average spectral irradiance measured during the study period was significantly greater in the fiberoptic phototherapy group (9.2+/-1.2 microW/cm2/nm vs 7.1+/-1.1 microW/cm2/mm, p < 0.05), conventional phototherapy was significantly more effective in decreasing bilirubin levels: the duration of exposure to phototherapy was significantly shorter (49.4+/-14.4 hours vs 61+/-13.1 hours, p < 0.05), and overall bilirubin decline rate as mg/dl/h and percent/h was significantly greater in the conventional phototherapy group (0.15+/-0.06 mg/dl/h vs 0.11+/-0.05 mg/dl/h, and 0.81+/-0.34 percent/h vs 0.60+/-0.28 percent/h, p < 0.05). There were four failures of phototherapy in the fiberoptic phototherapy group whereas no phototherapy failure was observed in the conventional phototherapy group (p < 0.05). The emission spectrum of the daylight fluorescent lamp revealed a broad emission between the violet and red spectra with tiny narrow peak emission bands in 405 nm, 436 nm, 546 nm and 577 nm, while a broad emission through the blue and green wavelengths (mainly in the green spectrum) without any peak emissions was detected in the tungsten-halogen lamp of the fiberoptic phototherapy system. Conventional phototherapy with daylight fluorescent lamps should be preferred to fiberoptic phototherapy administered with fiberoptic phototherapy and in the treatment of term newborns with nonhemolytic hyperbilirubinemia.